Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Allogene Therapeutics Q3 2026 Results: Net Loss of $50.4M, Loss Widens

Allogene Therapeutics reported a net loss of $50.4 million for the third quarter of 2026, an increase from the $41.4 million loss in the same period of 2025. The company strengthened its balance sheet through a public offering and ATM sales, ending the period with $392.6 million in total stockholders' equity compared to $292.5 million at the end of 2025.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.0
Net income-50.4-41.4
EPS (diluted, $ a share)$-0.15$-0.19

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: ALLO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Allogene Therapeutics, Inc.: key numbers

Share price
$0.8070Close, Nov 16
Market cap
$280M
Shares outstanding
346.47MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Allogene Therapeutics, Inc.

All →
4:13 PM ET 8-K
Financial Results

Allogene Therapeutics Financial Results

Allogene Therapeutics reported financial results for the third quarter of 2026, ending the period with $388.9 million in cash and investments. The company highlighted enrollment momentum in its pivotal Phase 2 ALPHA3 trial for cema-cel in LBCL and upcoming data presentations for its autoimmune candidate ALLO-329.

Term
Q3 2026

“We believe 2027 will be an important year for cema-cel and the field, with upcoming ALPHA3 data expected to provide important insights into the potential for CAR T to be integrated into existing practice patterns, earlier in the course of a patient’s disease and closer to where they receive care.”

Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer

“Both programs reflect our conviction that the future of CAR T will be shaped not only by what these therapies can do, but by how we make them more accessible and practical for patients.”

Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.